

**REMARKS**

**The Amendment**

Claim 25 is amended to recite “a pharmaceutical formulation comprising an antibody”. This support finds support, for example, in page 16, lines 11-12.

Claims 34, 35, 39, 40, and 42 are amended to have the claims depend from Claim 25 instead of Claim 33. This amendment finds support, for example, in Claims 25, 33, 34, 35, 39, 40, and 42 as originally filed.

Claim 36 is amended to replace “M” with “M<sup>-1</sup>”. This amendment finds support, for example, in page 18, lines 14-15.

Claim 39 is amended to recite “the patient”. This amendment is to indicate that “the patient” finds antecedent support in Claim 25, from which amended Claim 39 depends.

Claims 40-41 are amended to replace “said anti-interleukin 12 antibody” with “said antibody”. This amendment finds support, for example, in Claims 25, 33, 40, and 41 as originally filed.

No new matter is added to any of the above amendment. The Examiner is requested to enter the amendments.

**Remarks**

Claims 25-26 and 34-42 are pending in the present application.

**1. Objections under 37 CFR 1.75(c)**

Claim 33 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim.

Claim 33 is cancelled. The objection is thereby rendered moot and should be withdrawn.

**2. Information Disclosure Statement**